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THE INADEQUACIES of conventional immuno-
suppression with azathioprine and prednisone 
have been serious enough to prevent the full ex-
ploitation of organ transplantation procedures. 
The prospect of improving the situation was 
dependent upon new immunosuppression tech-
niques. In 1976, Borel and associates (2,3) de-
scribed the immunodepressive properties in mice, 
rats and guinea pigs of an extract from the fungi 
Cylindrocarpon lucidum and Trichoderma poly-
sporum. Cyclosporin A suppressed cellular and 
humoral immunity without bone marrow depres-
sion or other prohibitive organ toxicity. 
Clinical trials were begun in 1978 by Caine 
and co-workers (5, 7) in England with encourag-
ing results. In late 1979, cyclosporin became 
available for preliminary testing in the United 
States (28). We report herein a learning expe-
rience with this drug in 66 consecutive human 
recipients of 67 cadaveric renal homografts for 
whom follow-up periods of nine to 18 months are 
now available. 
\(ETHODS 
The mean age of the 66 patients was 39.2±9.9, 
S.D., years, a range of 18 to 61 years. There were 
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12 women and 54 men. Three of the patients had 
diabetes. Six were carriers of HbsAg virus, al-
though only one patient had other evidence of 
hepatic disease, Three patients had malignant 
hypertension which was thought to have caused 
the renal failure. Two patients had coronary ar-
tery disease and one patient had cardiomyopathy. 
Two other recipients were suspected of having 
coronary artery disease, the severity of which was 
underestimated preoperatively. 
The transplantations were primary in 57 pa-
tients. In the other nine, the patients were under-
going their second or third transplantation. No 
attempt was made to transfuse deliberately the 
recipients in advance of the operation. Many of 
them were referred from nephrology centers at 
which transfusion had been avoided. 
The matches of the recipients with their donors 
were poor. The number of mismatches at the 
HLA-A and B loci averaged 3.3±0,7, S.D., and 
only ten of the 66 patients had as few as two mis-
matches. At the D-related locus, there were no 
perfect matches in the 58 recipients for whom this 
information was available. 
The serums of all 66 recipients were analyzed 
for antibody content. Eleven of the primary and 
six of the secondary or tertiary graft recipients 
had warm anti-Tor anti-B lymphocyte an-
tibodies against more than 20 per cent of a panel 
obtained from 30 volunteers. Eight of the primary 
and three of the secondary or tertiary graft 
recipients had positive B-warm cross matches 
with the lymphocytes of theil' donors, There were 
no examples of transplantation against donor spe-
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TABLE I.-CA'CSE OF DEATH AND ITS RELATION TO f:s1~1DCklpDCmmobppflk 
Rt'naljuncllon 
Pallent Sa .. before dealh. RelalIOn of 
Age. yr. Pre-exISting Days posl- creatlnene. mgm. ImmunosuppressIOn 
Sex medlcal condlllOns Cause oj dealh (jperatwel) per cent la dealh 
Chronic aggressive Cerebral hemmorhage. recent 335 2.9 None 
45 hepatitis. HbsAg+ pulmonar\' no cardia 
F resolved 
15 Pulmonar\' and pleural Pulmonary emboli. 110 2.3 Yes 
28 granulomatosis. Pneumocystis carinii 
~1 probably histoplasmosis pneumonitis 
18 Coronary atherosclerosis Intrathoracic hemorrhage after 34 2.0 None 
46 coronary arlen' bypass 
M 
21 None Intra-abdominal and 222 Anephric Yes 
29 intracranial no cardia 
M infection: pancreatic necrosis 
27 !'Jone Pneumonia; seizures with 80 Anephric Yes 
29 aspiration 
M 
40 None Pneumonitis, pneumoc),stis 154 3.0 Yes 
39 carinii plus bacterial 
M 
45 Duodenal ulcer in remission Gastointestinal hemorrhage; 109 2.4 Yes / 
53 systemic infection 
M 
58 Coronary atherosclerosis Anaphylactic reaction to 20 1.9 None 
48 coronary angiography 
M contrast medium 
65 None Pneumonitis. Pneumoc\,stis 82 4.2 Yes 
60 carinii 
M 
M, Male; F. female; HbsAg. hepatitis B surface antigen 
cific T -warm antibodies which cause, as shown 
by Terasaki and colleagues (31), hyperacute re-
jection. 
Many of the first patients in our series (28) 
had pretreatment with thoracic duct drainage, 
lymphapheresis or cyclosporin A. The pretreat-
ment time was from a few days to almost three 
months and was well tolerated. However, the 
practice of pretreatment was discontinued be-
cause the results were not better than when im-
munosuppression with cyclosporin A was begun 
a few hours before operation. 
In the first part of the series, prednisone was 
withheld postoperatively until there were mani-
festations of rejection. \Vhen it became obvious 
that rejection occurred in about two-thirds of pa-
tients, treatment was standardized. 
On the day of, or the day before, operation and 
after, cyclosporin A was given at a dose of 17.5 
~-....... DI~I per kilogram per day. This was con-
«t.··· ..... ,.::u daily for two months, if possible. This dose 
decreased at the end of that time, or before in 
event of toxic side-effects, to the 1 0 milligrams 
kilogram per day range. For adults, predni-
sone was begun at a dose of 200 milligrams on the 
day of operation, with decrements of <1-0 milli-
grams for the next four days. On day 5, the dose 
was reduced from 40 to 20 milligrams. After this, 
weaning from the 20 milligrams per day was on 
the basis of the clinical course. Deviations from 
this plan were made if dictated by complications 
postoperatively, including the supervention of 
rejection. Rejections were treated with a 1 gram 
bolus of hydrocortisone plus a repeat five day 
course of high dose prednisone given orally, using 
reductions of 40 milligrams a day from a begin-
ning level of 200 milligrams. 
Tissues from renal homografts were examined 
with conventional histopathologic techniques. 
Special studies were performed for those patients 
who were suspected of having lymphomas. In 
these two patients, no fresh or frozen tissue was 
available. Fixed tissue was preserved for study by 
light microscopy, electron microscopy and im-
munoperoxidase techniques. For the immunoper-
oxidase studies, the specificity of the antiserums 
was established by the blocking and hemaggluti-
nation techniques of Mason (18), Taylor and 
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TABLE It-PATIENTS CHANGED FROM CYCLOSPO-
RIN A TO AZATHIOPRINE 
Craft 
functwn 
pnor to Present graft Time of 
change, function after change 
creatinine, change, after Indication for 
Patient mgm. per creatinine, mgm. transplant, therapeutic 
No. cent per cent mos. c'hanlJt! 
2 2.3 2.5 13 Hepatotoxicity 
3 3.1 1.4 8 Nephrotoxicity 
plus 
hepatotoxicity 
9 3.6 Graft loss 
2'h months later 6 Nephrotoxicity 
12 4.6 2.8 4 Nephrotoxicity 
14 3.6 2.1 10 Nephrotoxicity 
21 3.6 Graft loss 
2 weeks later 5 Nephrotoxicity 
Burns (30) and Zulman and collaborators (34). 
Immunoenzymatic staining was performed on 
paraffin embedded tissue sections, using either 
the peroxidase anti peroxidase technique of Stern-
berger and co-authors (29) or the labeled antigen 
technique of ~1ason and Sammons (19). For-
malin fixed material was treated with trypsin. X-
chromatin and Y -chromatin counts were per-
formed upon the tumor tissue using Feulgen 
stained preparations and quinacrine fluorescence 
microscopy, as described by Curran and Gregory 
(10) . 
Serums from these two patients were titrated 
for antivirus capsid antigen, IgG of Epstein-Barr 
virus by the indirect immunofluorescent method 
of Henle and Henle (11) and for anti virus capsid 
antigen IgM after sucrose density fractionation. 
Antibody to herpes simplex virus and cy-
tomegalovirus was sought by complement fixa-
tion. 
The clinical objectives of the trial were to learn 
the optimum way to use the drug and to see if the 
results were as good as, or better than, in the past 
with established methods of immunosuppression. 
Thus, randomized contemporaneous controls were 
not obtained. However, the results with primary 
cadaveric transplantation were compared with 
those during the preceding three years, using 
T.\BLE ilL-PRES ENT GRAFT Fl"NCTION IN L1FE-SL'S-
T.\INI.NG KIDNEYS 
SerUI1"l lTt'atznznf! 
.\l"an L'vdospor", .\fearl 
,·a/"". "'!frn. per .\"0. 'JI iOIl! rngm./ prednlpEFn~ dose 
cent patients k~mKjIjav ± SD mgm./dav ± S.D. 
S; 1.5 9 8.3",2.1 1~K~±PK~ 
1.6-2.5 26 -.:>", 1.8 17.3:2.9 
2.6-3.5 1 5 - J>± 1. 7 18.0±J.b 
~PKS 2 ~U·K 6.5t 10.20 
• Recurrent ox.alosis. 
tHas aCUle rejection. Cvclosponn dose recently was increased from 4.8 to 
6.S mdligrams per kilogram per day . 
conventional immunosuppression of aza 
and prednisone, with or without antilym 
globulins, and conventional immunosupp 
plus thoracic duct drainage preoperatively' 
postoperatively (27). Preoperatively, the 
phoid depletion was for at least 28 days. 
RESCLTS 
Patient SurvivaL 
Nine of the 66 patients died from 20 to 
days after transplantation (Table I) . At the 
of death, five of the nine patients had good, or e¥'i, 
cellent, graft function. Two of these five recipi:' 
ents died as a result of instrumentation for the 
diagnosis or treatment of coronary atherosclero_ 
sis. The first of these patients had a fatal ana-
phylactic reaction to the contrast medium. The 
second patient had a fatal hemorrhage after a cor-
onary artery bypass. A third patient of the five 
with good graft function died suddenly of a cere-
bral hemorrhage 11 months after transplantation. 
The deaths of these three patients were not con-
sidered to be related to immunosuppression. 
Infection with the opportunistic organisms 
commonly reported with conventional immuno-
suppression was a major factor in the deaths of 
six patients. Rejection had been diagnosed in all 
six, and increases in the dosage of prednisone had 
been used in unwise efforts to save the grafts. 
None of the patients died after cadaveric re-
transplantation. The actuarial patient survival of 
recipients of first kidneys has been slightly better 
than in the actual survival of retrospective con-
trols (Fig. 1), but not significantly so. 
Kidnev Su.rvlvaL 
Follow-up periods are now nine to 18 months 
for the 57 patients still living. Twenty-three sur-
vivors are alive more than a year. Fifty-two of the 
original 66 patients are free of dialysis. 
Primary cadaveric transplantation. Of the 57 
kidneys transplanted into 57 recipients, nine were 
placed in recipients who died and two more were 
lost to rejection. Th us. 80.7 per cent of the grafts 
are supporting life. The actuarial graft survival 
data are shown in Figure 2 in comparison with 
that actually achieved with other techniques of 
Immunosuppression. 
Cadal't.'Tlc retransplantatlOTl. Of ten kidneys 
transplanted into nine recipients, six are func-
tioning after 17, 16, 15. 14. 12 and 11 months. 
Three organs \",ere lost to rejection. The fourth 
was removed because of complete ureteral necro-
sis, after which retransplantation was successful-
I y carried out. 
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FIG. 1. Denver series of primary cadaveric kidney transplant. One year actuarial patient survival 
of S 7 recipients of primary grafts being treated with cvclosporin A and prednisone. Actual follow-up 
time is nine to 18 months. The results are compared with the actual one year patient survival using 
thoracic duct drainage preoperatively and postoperatively plus conventional immunosuppression 
and conventional immunosuppression alone. control. TDD, Thoracic duct drainage. 
FIG. 2. Denver series of primary cadaveric kidney transplant. One year actuarial graft survival of 
S7 primary cadaveric grafts under treatment with cyclosporin A and prednisone. Actual follow-up 
time is nine to 18 months. There were no exclusions. The results are compared with the actual one 
year survival of primary cadaveric kidneys under optimal treatment with thoracic duct drainage plus 
conventional immunosuppression and conventional immunosuppression alone. control. The p values 
were derived with the Student's t test. TDD, Thoracic duct drainage. 
Change to Azathioprine 
After four to 1311z months, cyclosporin A was 
stopped in six patients (Table II). In each in-
stance, nephrotoxicity was suspected. Within 13 
days to ten weeks, two of the recipients rejected 
their kidneys. The other four have had stable or 
improved renal function in the ensuing 12, 11, 
eight and four months. 
Renal Function 
The serum creatinine levels in the patients who 
died are given in Table I. Five living patients are 
anephric, three being in the retransplantation 
group and two, in the primary transplantation 
group. The serum creatinine concentrations in 
the 52 patients still bearing kidneys are summa-
rized in Table III. More than half of these 
recipients have satisfactory and stable function, as 
defined by a serum creatinine value of less than 
2.5 milligrams per cent. As previously reported 
by Caine and associates (5), a number of patients 
with clinically good results have slightly abnor-
mal renal function. 
Renal Histopathology 
Eleven kidneys became available for study 14 
"to 335 days after transplantation. In seven, im-
. munosuppression had been stopped for a sig-
.. nificant period previously (Table IV) , and six of 
these grafts showed evidence of rejection. In four, 
it was acute, superimposed in one instance upon 
chronic rejection, in one instance it was chronic, 
and, in another instance, acute rejection was just 
commencing. The seventh kidney was normal 11 
days after stopping immunosuppression, except 
for a few fibrin thrombi in glomerular capillaries 
and in arterioles. 
Four kidneys came from patients who had 
received continuous immunosuppression. Two of 
these showed changes of chronic rejection; in one 
patient, there was mild cellular infiltration, and 
in the fourth, there was no evidence of rejection. 
An unusual feature in three of the seven grafts 
which showed signs of acute rejection was the 
presence of eosinophils in the interstitial cellular 
infiltrate. One graft showed patchy acute tubular 
necrosis, but there was no morphologic evidence 
of a specific cyciosporin induced tubular lesion. 
Hospitalization and ;\1orbidity 
Duration of hospitalization in the last 30 
primary cadaver recipients was 15±6, S.D., days, 
a range of seven to 35 days. The total hospitaliza-
tion in the retrospective control groups was 
57±21, S.D., a range of 22 to 151 days with con-
ventional immunosuppression and 74± 13, S.D., 
days, a range of 51 to 135 d4 ys, after optimal 
thoracic duct drainage treatment. 
-. I 
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TABLE IV.-HISTOPATHOLOGY OF t I RENAL HOMO-
GRAFTS 
Patient 
.vo. 
I, P 
Conditions 
of 
sampling 
Autopsy 
9, P Nephrectomy 
12, R Nephrectomy, 
ureteral 
necrosis 
15, P Autopsy 
19, R Nephrectomy 
21, P Nephrectomy 
27, P !'Iephrectomy 
40, P Autopsy 
51, R Nephrectomy 
55, R Nephrectomy 
57, P Nephrectomy 
Days 
Time of without 
sampling CyA/aza-
after Ihlopnne 
transplant before 
days sampling Pathologic findings 
335 0 Some patchy proximal 
291 139/5 
16 o 
110 11 
46 
155 27 /8 
14 25 
154 11 
25 11 
44 
147 36 
tubular necrosis. No 
evidence of rejection 
Chronic rejection with 
mononuclear cell 
infiltration, 
obliterative arterial 
lesions and 
transparent 
glomerulopathy 
Minimal cellular 
infiltration and no 
vascular lesions 
No evidence of 
rejection. Few fibrin 
thrombi in 
glomerular 
capillaries and in 
arterioles 
Chronic rejection with 
mononuclear cell 
infiltration and 
obliterative arterial 
lesions 
Acute cellular and 
humoral rejection 
superimposed on old 
chronic rejection 
with obliterative 
arterial lesions 
Acute rejection with 
secondary oKalosis. 
Minimal cellular 
infiltration with rare 
arteriolar necrosis 
Acute cellular rejection 
Chronic rejection with 
mononuclear cell 
infiltration and 
obliterative arterial 
lesions 
!'I ecrOlic kidney 
secondary to acute 
rejection 
P. Primary transplant; R. retransplam; CyA. cyclosponn A. 
There was one deep wound infection. In addi-
tion to the infections 10 the patients who died, 
there were six examples of pneumonitis. These 
included three pneumocystis carinii, one example 
of nocardia and two of undetermined cause. One 
patient had an abscess of the lung which was 
treated with left lower lobectomy after immuno-
suppression was stopped. Eight patients had 
herpes simplex at some time. There were no 
examples of herpes zoster. Miscellaneous in 
tions included histoplasmosis, amebic colitis 
three examples of pneumocystis carinii in addi_, 
tion to the patients who had this diagnosis at au;. 
topsy. ;~K 
The well-being of patients treated with cyclo-
sporin A was remarkable, mainly because of the 
low dosages of prednisone, which usually were in 
effect by the end of five days. Hirsutism, gum 
hyperplasia, flushing and paresthesias after drug 
ingestion and tremors, as described by Caine and 
colleagues (7) and us (28), were minor an-
noyances. Liver function abnormalities were seen 
in 13 of the 66 patients, but these receded with 
dosage reduction in all but one instance. Cyclo-
sporin was changed to azathioprine in the excep-
tional patient, 13 months after transplantation. 
Nephrotoxicity of cyclosporin A was suspected 
in 15 of the patients, while dosages of 17.5 milli-
grams per kilogram per day were being given. All 
improved when dosages were lowered. The dis-
tinction between nephrotoxicity and rejection was 
too imprecise to permit the acq uisition of decisive 
data about the true incidence of nephrotoxicity. 
LymphoproliJerative Complications 
Patient 8 was a 25 year old woman in whom 
perforation developed in the mid-small intestine 
157 days after transplantation. She was treated 
with segmental intestinal resection. Her cydo-
sporin dose was reduced from 15.8 to 5.9 milli-
grams per kilogram per day. She has had no 
known recurrence in the ensuing nine months. 
In the base of the perforated ulcer, there were 
B cells, as described by Lukes and Collins (16) in 
their classification scheme for lymphoprolifera-
tive disorders. Determination of intracellular im-
munoglobulins by immunoperoxidase techniques 
indicated that the B cells were polyclonal, 95 per 
cent of the cells producing alpha and 5 per cent, 
gamma heavy chains. The kappa light chain to 
lambda light chain ratio was 6: 1. The B cells 
showed female chromatin markers, that is, they 
were of host origin because the donor was male. 
The lesion was officially designated a lympho-
proliferative reaction, not a lymphoma. 
Patient 15 died of pulmonary emboli and 
pneumocystis pneumonia 110 days after trans-
plantation. At autopsy, an incidental finding was 
small nodular deposits of B cells in the retroperi-
toneal and para-aortic lymph nodes, in the 
spleen, in the liver and in the heart. ~lost of the 
deposits were necrotic. Immunoperoxidase tech-
niques revealed that the B cells were monoclonal 
and that many of them were producing mu heavy 
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chains and kappa light chains. The origin of the 
cells could not be determined because the host and 
donor were of the same sex. 
In both patients, the stored serums before and 
after renal transplantation were examined for an-
tibodies against the Epstein-Barr virus. In both 
instances, the antiviral capsid antigen titer rose 
significantly after renal transplantation (Tables 
V and VI). In Patient 8, this was the result of a 
primary infection (Table V). Patient 15 had an-
tibody before transplantation, suggesting reac-
tivation of Epstein-Barr virus. Neither patient 
showed increased antibody production to cy-
tomegalovirus or herpes simplex virus. 
DISCUSSION 
The need to develop better immunosuppressive 
therapy can be illustrated by the multicenter com-
pilations of data of Opelz and co-workers (22) 
and McDonald and co-authors (20). With con-
ventional immunosuppression, they reported that 
less than half of the primary cadaveric grafts were 
functioning at the end of the first postoperative 
year. The outlook after cadaveric retransplant a-
tion has been even less encouraging (13). Even 
with success, the quality of life has too often been 
degraded by the need for chronic treatment with 
high dosages of steroids. 
The consequence has been a reluctance by 
many responsible nephrologists to advise cada-
veric renal transplantation or a disinclination of 
their patients to accept such a recommendation. 
The economic impact has been staggering as the 
number of patients maintained in renal dialysis 
centers has swelled without a commensurate 
decompression by transplantation. Efforts to im-
prove the situation with tissue matching or by 
adding antilymphocyte globulin, total lymphoid 
irradiation and thoracic duct drainage to azathio-
prine-prednisone therapy have been of question-
able efficacy on one hand or too expensive or in-
convenient on the other for general applicability, 
or both. 
Thus far, the trials with cyclosporin A have es-
caped such disillusionment. However, they have 
raised questions about the optimal use of this 
agent, which will have to be taken into considera-
tion by those planning randomized trials. The 
most persistent of the questions has been whether 
or not to use cyclosporin A as the sole immuno-
·suppressive therapy, as practiced by CaIne and 
collaborators (5, 6, 7) or to combine it from the 
': beginning with prednisone, as we have recom-
mended (26, 28) . The view of CaIne was based, 
.. in part, upon his recognition that cyclosporin A 
TABLE V.-ANTIBODY CHANGES IN PATIENT EIGHT 
AntiviraE capSId 
Date, _antigen of Epstem·Barr uzrus_ Paul Bunnell 
7980 IgG IgM test 
Jan. 3 .. <8 neg. <10 
10 ...... <8 neg. <10 
J7 ...... <8 neg. <10 
24 .. <8 neg. <10 
31 ...... <8 neg. <10 
renal transplant 
Feb. 7 . . <8 neg . <10 
14 ...... <8 neg. <10 
21 . 16 pos. 40 
27 .. febrile illness 
28 ...... 64 pos. 80 
July 5 ...... 64 pos. <10 
lymphoma resected 
10 ...... 64 pos. <10 
17 ...... 64 pos. <10 
possessed nephrotoxic properties which could 
mimic rejection and, thereby, precipitate steriod 
therapy for which there was no indication. In 
about half of our kidney recipients, the clinical 
diagnosis of rejection has been made either early 
or late. Renal specimens were not taken for 
biopsy. However, structural signs of rejection al-
most always were present in kidneys retrieved at 
autopsy or by graft nephrectomy. Moreover, in 
recipients of orthotopic livers in whom graft biop-
sies were systematically obtained, histopathologic 
evidence of rejection was found in the majority of 
patients (26). With both organs, the rejections 
were less violent than with conventional immuno-
suppression, and usually, they were highly re-
sponsive to adjustments of steriods. 
Because of the issue of nephrotoxicity, CaIne 
and associates (5, 6, 7) recommended delaying 
therapy with cyclosporin A until a vigorous di-
uresis was in effect, in the belief that many of the 
early an urias in their series were caused by cyclo-
sporin A rather than by immunologic factors. 
Because our observations were interpreted con-
versely, we have begun cyclosporin A before the 
operation with the intention of having a thera-
peutic blood level when the graft was vascular-
ized. There has been no obvious disadvantage 
from this practice. 
Nevertheless, nephrotoxicity as a management 
problem has been established unequivocally, 
since the early reports of CaIne and co-workers 
(5, 7). Powles and associates (24) have reported 
azotemia in bone marrow recipients, and we have 
seen the same thing after successful orthotopic 
liver transplantation (15, 26). Fortunately, the 
complication usually has reversed with a reduc-
tion of the cyc1osporin A dosage (15, 26, 28). In 
kidney recipients, the interface between effective 
immunosuppression and nephrotoxicity may be 
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TABLE VI.-ANTIBODY CHANGES IN PATIENT 15 
Date 
24 Oct. 1979 ................ . 
19 Feb. 1980. . ........... . 
21 Feb. 1980 ................ . 
28 Feb. 1980.. . ...... . 
6 Mar. 1980 .. 
1 5 ~fay 1980. . ........... . 
22 May 1980 .......... . 
29 May 1980 ........... . 
8 June 1980 ....... . 
AntIViral capsid 
antigen of Einstein-Barr virus, 
/gC 
8 
renal transplant 
8 
8 
8 
16 
64 
256 
Died 
lymphoma diagnosed 
at autopsy 
difficult to define_ We have tried to maintain the 
potentially nephrotoxic daily dose of 17.5 milli-
grams per kilogram for the first two postoperative 
months, even if there is imperfect, but life-sus-
taining, renal function, believing that a sub-
sequent reduction will be less apt to allow rejec-
tion and knowing that nephrotoxicity usually can 
be relieved by a reduction in the dosage at that 
time. 
Even long after transplantation, minor azo-
temia and hypercreatinemia seen in many pa-
tients receiving cyclosporin A may represent a 
low grade nephrotoxicity which does not vitiate 
the value of the drug. Since results of none of the 
histopathologic studies showed evidence by light 
or electron microscopy of a specific lesion induced 
by cyclosporin, we have concluded that cyclospo-
rin A can be used for chronic therapy. As a last 
resort, a change to azathioprine can be made, but 
at a considerable risk of subsequent rejection. 
Most of the other side-effects of cyclosporin A 
have not been serious, including gum hyper-
plasia, tremor and regional flushing or vague ab-
dominal discomfort just after drug ingestion. 
Although hepatotoxicity is seen in about one-fifth 
of the patients, this has been serious enough to 
necessitate a change to azathioprine in only one 
patient, more than a year postoperatively. 
The most publicized question about cyclospo-
rin has concerned its potential oncogenicity. It has 
been known for 15 years that the price of conven-
tional immunosuppression is an increased inci-
dence of de novo tumors. In the recent collection of 
Penn (23), approximately one-third were lym-
phomas. Thus. early reports by CaIne and col-
leagues (5) of lymphomas in patients treated 
with cyclosporin .\ were neither surprising nor 
dismaying. There was one example in the present 
series. It was not responsible for mortality. To 
our knowledge, no epithelial tumors have been 
seen in renal recipients. As experience with cyclo-
sporin A has accumulated \vorldwide, the spector 
of this drug being a spectacular tumor p 
has receded. . 
Most malignant lymphomas of B-cell type a~eK 
monoclonal and produce immunoglobulin of a" 
single light chain type. As described by Warnke 
and collaborators (33), IgM is the most fre-
quently expressed heavy chain and Patient 15 in 
our series conforms to this pattern. 
Several of the so-called lymphomas that have 
occurred after organ transplantation resemble the 
lesion found in Patient 8 in our study in that they 
have been reported as polyclonal by Borzy and 
co-authors (4) and Hertel and associates (12). 
Other post-transplant lymphomas reported by 
Crawford and colleagues (9) and Warnke and 
co-workers (33) have not borne immunoglobu-
lin, and it has not been possible to determine their 
clonality. 
Reactivation of Epstein- Barr virus after renal 
transplantation is common, and as in Patient 15 
in our series, this has occasionally been associated 
with the discovery of an immunoblastic sarcoma, 
as summarized by ~larker and collaborators 
(17). A primary Epstein-Barr infection after 
renal transplantation is rare, and it is interesting 
that, of the few instances recorded, one has been 
said by Nagington and Gray (21) to have been 
associated with lymphoma. The findings were 
similar to those of Patient 8 in our study in whom 
the final diagnosis was immunoproliferative reac-
tion rather than lymphoma. In two immuno-
blastic sarcomas in transplant recipients studied 
by Nagington and Gray (21) with Epstein-Barr 
virus deoxyribonucleic acid cytohybridization, 
Epstein-Barr virus deoxyribonucleic acid was 
found to be present in a significantly high concen-
tration in the lymphoma. In a patient studied by 
Crawford and co-authors (9), Epstein-Barr virus 
nuclear antigen was demonstrated in the tumor 
cells. 
Unfortunately, these latter investigations could 
not be performed upon the patients in our study. 
The increased antivirus capsid antigen observed 
in the patients in our series with lymphoprolifer-
ative disorders was not part of a general increase 
in antibody production. The same thing was 
noted by :\'agington and Grav (21) who won-
dered if the explanation might be a specific 
depression by cyclosporin .\ of the suppressor T 
cell related to Epstein- Barr virus infected lym-
phocytes. If this is correct, the defective suppres-
sor cell function might then permit the simultane-
ous expression of many clones of B cells, resulting 
in a polyclonal immunoblastic lesion. Bird and 
~lciachlan (1) and Crawford and associates (8) 
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provided some evidence in vitro to suggest that cy-
closporin A may specifically delete or inactivate T 
cells, but little is known of its effect in vivo. 
In an earlier report by I watsuki and colleagues 
(14) it was asked if the so-called lymphomas 
developing under conventional immunosuppres-
sion had the same lethal behavior as those in non-
immunosuppressed patients. The same question 
must be raised in patients treated with cyclospo-
rin A. Only time will tell whether or not these 
lymphoproliferative disorders will behave in the 
same way as apparently identical tumors in non-
immunosuppressed individuals. So far, in our ex-
perience and in that of CaIne and co-workers (6), 
no deaths have been attributable to de novo malig-
nant lesions which rose under cyclosporin A ther-
apy. In our hands, the incidence of lymphoma has 
been less than 1 per cent in a total experience now 
totaling 123 patients, the only unequivocal exam-
ple being patient 15 herein reported. 
Unless some other, as yet unrecognized, side-
effect emerges to limit the usefulness of cyclospo-
rin A, this agent should permit significant ad-
vances in whole organ transplantation. The early 
results in our preliminary trial were as good as, 
or better than, in any previous series of cadaveric 
transplantations done at our institution, in spite 
of the inclusion of many recipients who were at 
higher than average risk because of advanced age, 
vascular disease, hepatitis carrier state and di-
abetes mellitus. These patients participated in the 
learning process with a new technique and one 
which was in no sense standardized until near the 
end of the trial. Yet, 79 per cent of the recipients 
of randomly matched cadaveric organs are dialy-
sis-free and, in most instances, with good or ex-
cellent renal function after nine to 18 months. 
Five patients are anephric and nine have died. 
It is evident that most of the deaths were preven't-
able. The patients with coronary artery disease 
should have been treated more aggressively before 
transplantation. Most of the infectious deaths 
Were attributable to unwarranted persistence at 
salvage of the kidneys. The lesson has been 
taught by Salvia tierra and collaborators (25), 
:rilney and co-authors (32) and many others us-
mg conventional immunosuppression. 
SUMMARY 
. From nine to 18 months ago, 66 patients were 
gtyen 67 randomly matched cadaveric kidneys 
With cyclosporin A and steroid therapy. Nine of 
the recipients were undergoing retransplantation. 
The over-all kidney survival rate to date has been 
. 6 per cent, and 78.8 per cent of the recipients 
are dialysis-free. The patient mortality in this 
learning phase was 13.3 per cent. Nephrotoxici-
ty, hepatotoxicity and other side-effects of cyclo-
sporin A could usually be dealt with by dosage 
adjustments, making feasible the chronic use of 
this agent. One B-cell immunoblastic sarcoma 
was encountered which was monoclonal. It was 
not responsible for death. Another patient had a 
perforation of the intestine from a lympho-
proliferative reaction in which the B cells were 
polyclonal. After jejunal resection a year ago, 
there were no further complications. This lesion 
was not classified as a lymphoma. Both lympho-
proliferative lesions were associated with a rise in 
antibody to viral capsid antigen of Epstein-Barr 
virus. Results of this study have verified the 
effectiveness and relative safety of cyclosporin 
A with steroids for immunosuppression in human 
recipients of cadaveric kidneys. 
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